|1.||Abrahamse, Heidi: 2 articles (03/2012 - 07/2011)|
|2.||Manoto, Sello Lebohang: 2 articles (03/2012 - 07/2011)|
|3.||Houreld, Nicolette Nadene: 1 article (03/2012)|
|4.||Sekhejane, Palesa Rose: 1 article (03/2012)|
|5.||Vicente, M Graça H: 1 article (01/2012)|
|6.||Verberne-Sutton, Susan D: 1 article (01/2012)|
|7.||Hu, Xiaoke: 1 article (01/2012)|
|8.||Ongarora, Benson G: 1 article (01/2012)|
|9.||Garno, Jayne C: 1 article (01/2012)|
|10.||Lin, Hong: 1 article (08/2007)|
04/01/2007 - "Tumor remission was observed with ZnPcS(4) doses as low as 0.25 mg/kg. A conservative starting dose of ZnPcS(4) was arrived at on the basis of mouse toxicosis findings. "
03/01/2012 - "This study aimed to determine subcellular localization of ZnPcS(mix) and its effect on two cancer cell lines. "
04/01/2007 - "In tumor-bearing dogs, ZnPcS(4) doses <or= 4 mg/kg induced no signs of toxicosis and resulted in partial to complete tumor responses in 10 of 12 dogs 4 weeks after PDT. "
01/01/2012 - "Di-cationic Zn(II)-phthalocyanines (ZnPcs) are promising photosensitizers for the photodynamic therapy (PDT) of cancers and for photoinactivation of viruses and bacteria. "
04/01/2007 - "To determine the threshold for acute toxicosis of parenterally administered zinc phthalocyanine tetrasulfonate (ZnPcS(4)), a candidate second-generation photosensitizer, in mice and evaluate the compound's safety in a phase I clinical trial of ZnPcS(4)-based photodynamic therapy (PDT) in pet dogs with naturally occurring tumors. "
|2.||Lung Neoplasms (Lung Cancer)
07/01/2011 - "This in vitro study evaluated the effectiveness of a Zn sulfophthalocyanine (ZnPcS(mix)) as a potential photosensitizer in the treatment of human lung cancer. "
03/01/2012 - "It has been previously shown that mixed sulfonated metallophthalocyanine complex, zinc sulfophthalocyanine (ZnPcS(mix)) is effective in destroying lung cancer cells. "
08/01/2007 - "The aim of this sutdy was to demonstrate the selective localization of a new photosensitizer, zinc phthalocyanine tetrasulfonate (ZnPcS(4)), in rat eyes and investigate the ability of ZnPcS(4) to produce a photochemical closure of experimental choroidal neovascularization (CNV) upon irradiation with a 670-nm laser light. "
|4.||Photosensitivity Disorders (Photodermatitis)
02/01/1997 - "In order to optimize the photosensitization of mitochondria, we prepared the new cationic zinc (II) phthalocyanines with lipophilic side-chains (2,9,16,23-tetrakis (trimethylammonio) zinc (II) phthalocyanine tetramethylsulphate (ZnPcA1) and 2,9,16,23-tetrakis(hexyldimethylammonio) zinc (II) phthalocyanine tetramethylsulphate (ZnPcA6)) and compared them with the known cationic lipophilic sensitizers 2,9,16,23-tetrakis[2-(trimethylammonio) ethoxy]zinc (II) phthalocyanine tetraiodide (ZnPcE1) and 2,9,16,23-tetrakis[2-(hexyldimethylammonio) ethoxy] zinc (II) phthalocyanine tetrabromide (ZnPcE6) and the anionic hydrophilic sulphonated sensitizer ZnPcS. "
|4.||P-2 (P 2)
|5.||Photosensitizing Agents (Photosensitizers)
|6.||Zn(II)-phthalocyanine (zinc phthalocyanine)
|2.||Photochemotherapy (Photodynamic Therapy)